Risk factors for relapse in chronic hepatitis C patients who have achieved end of treatment response

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 5, 2010, Pages 957-963

  Shin, Su Rin ^a   Sinn, Dong Hyun ^c   Gwak, Geum Youn ^b   Cho, Moon Seok ^b   Lee, Joon Hyoek ^b   Koh, Kwang Cheol ^b   Yoo, Byung Chul ^b   Paik, Seung Woon ^b  

^a Hallym University   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c Armed Forces Taejeon Hospital   (South Korea)

Author keywords

Chronic hepatitis C; End of treatment response; Peginterferon; Relapse; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; HEMOGLOBIN; PEGINTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA; ERYTHROPOIETIN; ALPHA INTERFERON; ALPHA2A INTERFERON; ANTIVIRUS AGENT; HEPATITIS C ANTIBODY; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; DIABETES MELLITUS; FEMALE; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK PATIENT; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RELAPSE; RETROSPECTIVE STUDY; RISK FACTOR; THROMBOCYTE; TREATMENT DURATION; TREATMENT RESPONSE; AGE; ANTIVIRAL THERAPY; CHRONIC HEPATITIS C; FIBROSIS; SEX; BIOPSY; BLOOD; DRUG COMBINATION; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; IMMUNOLOGY; LIVER; MEDICATION COMPLIANCE; MIDDLE AGED; PATHOLOGY; RECURRENT DISEASE; RISK ASSESSMENT; SOUTH KOREA; STATISTICAL MODEL; TIME; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ADULT; AGE FACTORS; ANTIVIRAL AGENTS; BIOPSY; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RECURRENCE; REPUBLIC OF KOREA; RIBAVIRIN; RISK ASSESSMENT; RISK FACTORS; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 77951753027     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2009.06176.x     Document Type: Article

References (27)

1. Lauer GM, Walker BD. Hepatitis C virus infection. N. Engl. J. Med. 2001 345 : 41 52.
2. Shiffman ML. Optimizing the current therapy for chronic hepatitis C virus: peginterferon and ribavirin dosing and the utility of growth factors. Clin. Liver Dis. 2008 12 : 487 505, vii.
3. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004 39 : 1147 1171.
4. Berg T, von Wagner M, Nasser S et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006 130 : 1086 1097.
5. Hadziyannis SJ, Sette H Jr., Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 2004 140 : 346 355.
6. Shiffman ML, Suter F, Bacon BR et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N. Engl. J. Med. 2007 357 : 124 134.
7. Yu ML, Dai CY, Huang JF et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007 56 : 553 559.
8. Sanchez-Tapias JM, Diago M, Escartin P et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006 131 : 451 460.
9. Basso M, Giannini EG, Torre F, Blanchi S, Savarino V, Picciotto A. Elevations in alanine aminotransferase levels late in the course of antiviral therapy in hepatitis C virus RNA-negative patients are associated with virological relapse. Hepatology 2009 49 : 1442 1448.
10. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002 36 : S237 44.
11. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 : 958 965.
12. Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J. Is an 'a la carte' combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 2000 31 : 211 218. (Pubitemid 30033709)
13. Berg T, Sarrazin C, Herrmann E et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003 37 : 600 609.
14. Tsui JI, Currie S, Shen H, Bini EJ, Brau N, Wright TL. Treatment eligibility and outcomes in elderly patients with chronic hepatitis C: results from the VA HCV-001 Study. Dig. Dis. Sci. 2008 53 : 809 814.
15. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 1998 339 : 1485 1492.
16. Zeuzem S, Buti M, Ferenci P et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J. Hepatol. 2006 44 : 97 103.
17. Marcellin P, Heathcote EJ, Craxi A. Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the 'accordion' regimen? J. Hepatol. 2007 47 : 580 587.
18. Kim KT, Han SY, Kim JH et al. [Clinical outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C]. Korean J. Hepatol. 2008 14 : 36 45.
19. Lee H, Choi MS, Paik SW et al. [Peginterferon alfa-2a plus ribavirin for initial treatment of chronic hepatitis C in Korea]. Korean J. Hepatol. 2006 12 : 31 40.
20. Lee HJ, Eun JR, Choi JW, Kim KO, Moon HJ. [Comparison of therapeutic results between combination therapy of peginterferon alpha-2a plus ribavirin and interferon alpha-2b plus ribavirin according to treatment duration in patients with chronic hepatitis C]. Korean J. Hepatol. 2008 14 : 46 57.
21. McHutchison JG, Manns M, Patel K et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002 123 : 1061 1069.
22. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003 38 : 645 652. (Pubitemid 37052151)
23. Shirakawa H, Matsumoto A, Joshita S et al. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology 2008 48 : 1753 1760.
24. Yu ML, Dai CY, Huang JF et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008 47 : 1884 1893.
25. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009 49 : 1335 1374.
26. Tarantino G, Conca P, Sorrentino P, Ariello M. Metabolic factors involved in the therapeutic response of patients with hepatitis C virus-related chronic hepatitis. J. Gastroenterol. Hepatol. 2006 21 : 1266 1268.
27. Soresi M, Tripi S, Franco V et al. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis. Liver Int. 2006 26 : 1119 1125.